Summary data to the end of April 2016A total of 1,951 children were reported to CHIPS by the end of April 2016, comprising virtually all of those receiving HIV-related care in the UK and Ireland from 2006 onwards. In 2010, 89 children were newly reported to CHIPS, and similarly 57 in 2011, 54 in 2012, 43 in 2013, 25 in 2014 and 32 in 2015, with the decline partly due to reporting delay of new cases to the NSHPC, as well as ascertainment of infection status in infants born in the UK and Ireland. Of the 1,951, 110 children were known to have died whilst receiving paediatric care, including six deaths in 2009, two in 2010 and two in 2011. There has been no deaths reported in paediatric care from 2012.
To date 792 young people left paediatric care and transitioned to adult clinics, with 50-100 patients transferring each year between 2009 and 2015. The median age at transfer was 17.6 years (IQR 16.7-18.5). Thus the number of children in CHIPS is gradually declining, with fewer new diagnoses and increasing numbers transferring to adult care.
Of the 1,951 ever followed in CHIPS, 43% were born in the UK or Ireland, 55% were born abroad and 2% unknown. For those born in the UK or Ireland, the median age at first presentation has been relatively constant at around 6-18 months although 16% did not present until ≥ 5 years of age. For children born abroad, the median age at first presentation increased from around 6 years in 1997-2004 to 10-12 years from 2009 onwards. Similarly the age distribution by year of follow-up in paediatric care has changed considerably over the years. In 2000 the median age at last follow up was 7 years (inter-quartile range, IQR 4-10). In 2016, among patients on follow up in paediatric care, the median age at time of last visit was 14.5 (IQR, 11.2-16.5). The proportion of the cohort on active follow up aged ≥ 15 years at last visit was 48% in 2016. The rate of hospital admissions in the cohort has declined from 52 per 100 child years in 2000 to 9.0 in 2014 (data for 2015 was not reported due to reporting delay). Viral load suppression among those starting combination ART naïve has improved with calendar time: 39% suppressed viral load ≤ 50c/ml  at 12 months in 2000-2004, increasing to 74% for 2010 onwards.
As of the end of April 2016, a total of 905 patients were alive and in active follow-up at a paediatric clinic in the UK or Ireland. Of these, just over half (53%) were female, 50% were born in the UK or Ireland, 78% were of black African ethnicity, and nearly all (93%) were known to have been infected through mother-to-child transmission. Forty-six per cent of children were being seen at clinics in London, 42% in the rest of England, 4% in Scotland, 1% in Wales, 6% in the Republic of Ireland, and 1% in Northern Ireland. Under one-quarter (23%) had progressed to CDC stage C and another quarter (25%) to CDC stage B during follow-up. Among patients with a follow up visit since January 2014 (n=828), 50 children (6%) were ART naïve (the large majority of whom (n=39, 78%) were aged ≥ 10 years at time of last visit), 9% of patients were on mono or dual therapy, 80% were on a 3-drug combination antiretroviral regimen and 6% were on regimens including ≥ 4 drugs. Among patients on ART, with viral load measures available in 2013 (n=744), 82% had confirmed viral load <400 copies/mL and 73% were suppressed <50 copies/mL.
Numbers are based on reports received rather than children seen to the end of April 2016. 2015/16 data are subject to reporting delay and may therefore be incomplete.
 ≤ lower limit of detection of the assay if the lower limit was >50 but ≤ 400c/ml.